IFNG and systemic lupus erythematosus: For example, the (+)-JQ1 compound simultaneously targeted seven diagnostic genes in the network, and in vitro treatment of CD4+ T cells from SLE patients with JQ1 has been reported to reverse immune dysregulation and reduce inflammatory cytokines such as IFN-γ and IL-21 (Gao et al., 2018), suggesting that it could be a potential SLE therapeutic drug.